![Patrice Rioux](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrice Rioux
Founder at THIOGENESIS THERAPEUTICS, CORP.
Net worth: 3 M $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kim Tsuchimoto | F | 61 | 9 years | |
Christopher Starr | M | 71 | 10 years | |
Brook Riggins | M | 58 | - | |
Chandler Robinson | M | 40 | 10 years | |
Vincent P. Stanton | M | - |
Thiogenesis Therapeutics, Inc.
![]() Thiogenesis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thiogenesis Therapeutics, Inc. engages in the development of novel compounds that are based on thiols, thiol derivatives or S-H groups. The company was founded by Patrice P. Rioux and Vincent P. Stanton and is headquartered in Belmont, MA. | - |
Michael Brown | M | 67 | 10 years | |
Arthur Klausner | M | 64 | 7 years | |
Raymond Anderson | M | 82 | 7 years | |
W. Mullally | M | 50 | 6 years | |
Andrew Cittadine | M | 52 | 3 years | |
Laura Kelly | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 years |
Julie Smith | F | 53 |
Raptor Pharmaceuticals, Inc.
![]() Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 4 years |
Andrew Mazar | M | 62 | 8 years | |
Todd C. Zankel | M | 60 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 3 years |
Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 4 years |
Marc Patrick Reichenberger | M | 59 |
Raptor Pharmaceuticals, Inc.
![]() Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | - |
Suzanne Bruhn | M | 60 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 years |
Vijay Samant | M | 77 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 3 years |
Craig Johnson | M | 62 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 1 years |
Karl Cahill | M | 51 |
Raptor Pharmaceuticals Corp.
![]() Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | - |
Justin Ford | M | - |
Raptor Pharmaceuticals, Inc.
![]() Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 3 years |
Octávio Costa | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 11 | 47.83% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrice Rioux
- Personal Network